Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03049072Recruiting

Ion Therapy Patient Registry

Role: lead

NCT04894643Not ApplicableRecruiting

Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer

Role: lead

NCT05191940Not ApplicableRecruiting

Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)

Role: lead

NCT06390657Withdrawn

Radiotherapy Treatment Planning Comparison Using SBRT-PATHY (Photons) Versus CARBON-PATHY for Unresectable Bulky Tumors

Role: lead

NCT04875871Not ApplicableTerminated

Particle-based Partial Tumor Irradiation of Unresectable Bulky Tumors

Role: lead

NCT03740191Not ApplicableTerminated

Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer

Role: lead

All 6 trials loaded